(Reuters) - Cigna said on Monday it will remove AbbVie’s blockbuster rheumatoid arthritis drug Humira from some of its lists of preferred drugs for reimbursement in 2025, and recommend less pricey ...

AbbVie has successfully managed the patent expiration of its top-selling drug Humira by delaying revenue decay, introducing new products, and expanding its pipeline. The company is committed to ...

近日，2025年全球TOP50药品销售额完整版榜单正式揭晓，这份涵盖2020-2025年六年数据的榜单，不仅勾勒出全球重磅药的销量变迁，更暗藏着医药行业的迭代逻辑——旧霸主落幕、新明星崛起，靶点赛道的竞争格局正被彻底改写。

AbbVie is a leading pharmaceutical company with a diverse portfolio of products and strong revenue growth. The company has a solid track record of increasing dividends and offers an attractive current ...

North Chicago-based drugmaker AbbVie must pay back Medicare for raising the price of its blockbuster drug Humira too quickly, the federal government said Wednesday. The penalty follows years of ...

Humira (adalimumab) treats certain types of arthritis and inflammatory diseases. This prescription drug is a liquid for injection under your skin. Humira may not be safe to receive while pregnant but ...

Adalimumab is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, chronic psoriasis, hidradenitis suppurativa, and ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

AbbVie Inc’s (NYSE:ABBV) top-selling arthritis drug, Humira, has managed to retain over 80% of its patients even after facing nine lower-priced rivals in the U.S. over the past year, Reuters reports.

AbbVie recently reported record 2025 results and outlined a stronger 2026 outlook, while advancing key immunology assets and completing the VOLITE skin quality aesthetics trial to bolster its ...

AbbVie’s ABBV rheumatoid arthritis drug Humira, one of the top-selling biopharmaceutical products of all time, will have new lower-cost competition starting Saturday. But even as nearly identical ...